Pitavastatin

Description

Pitavastatin · CAS 147511-69-1 · C25H24FNO4. UNII M5681Q5F9P.

Identification

Computed Descriptors

Physical description & handling notes

• Very slightly soluble
• 202.3 Ų [M+H]+ [CCS Type: DT; Buffer gas: N2; Ionization: APCI+; Dataset: TOXCAST; Source Identifier: DTXSID4046448]
• 203.2 Ų [M+H]+ [CCS Type: DT; Buffer gas: N2; Ionization: ESI+; Dataset: TOXCAST; Source Identifier: DTXSID4046448]
• 207.8 Ų [M-H]- [CCS Type: DT; Buffer gas: N2; Ionization: ESI-; Dataset: TOXCAST; Source Identifier: DTXSID4046448]
• 196.7 Ų [M+Na]+ [CCS Type: DT; Buffer gas: N2; Ionization: ESI+; Dataset: TOXCAST; Source Identifier: DTXSID4046448]
• MW: 493.45. MP: 138-139 °C. Specific optical rotation: +8.84 deg at 32 °C/D (c = 0.92 in chloroform). Soluble in acetonitrile /Pitavastatin lactone/

GHS Hazard Classification

Documented Uses

• Hydroxymethylglutaryl-CoA Reductase Inhibitors
• Preparation: Y. Fujikawa et al., European Patent Office patent 304063; eidem, United States of America patent 5011930 (1989, 1991 both to Nissan Chem. Ind.)
• Pitavastatin is a relatively newly developed cholesterol lowering agent (statin) that is associated with mild, asymptomatic and self-limited serum aminotransferase elevations during therapy, but has had limited use and has yet to be linked with clinically apparent acute liver injury.
• Breast Feeding; Lactation; Milk, Human; Anticholesteremic Agents; Hypolipidemic Agents; Hydroxymethylglutaryl-CoA Reductase Inhibitors
• Livalo is indicated as an adjunctive therapy to diet to reduce elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), triglycerides (TG), and to increase HDL-C in adult patients with primary hyperlipidemia or mixed dyslipidemia. /Included in US product label/
• The American College of Cardiology (ACC)/American Heart Association (AHA) cholesterol management guideline recommends statins as first-line therapy for prevention of atherosclerotic cardiovascular disease (ASCVD) in adults. Pitavastatin may be used for primary or secondary prevention in adults when moderate-intensity statin therapy is indicated. /NOT included in US product label/

Synonyms

Pitavastatin; 147511-69-1; Itavastatin; pitavastatine; NK 104; pitavastatinum; Pitavastatina; (3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid; NK-104; NIKITA; 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)-; M5681Q5F9P; (3R,5S,6E)-7-(2-Cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)-3,5-dihydroxyhept-6-enoic acid; (E,3R,5S)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid; NSC-760423; K-924 component Pivastatin

Frequently Asked Questions

What are the CAS number and molecular formula of Pitavastatin?

CAS 147511-69-1; molecular formula C25H24FNO4; molecular weight — g/mol.

What other names is Pitavastatin known by?

Pitavastatin, 147511-69-1, Itavastatin, pitavastatine, NK 104, pitavastatinum.

Is Pitavastatin classified as hazardous?

Hazard statements reported: H361, H362.

Facts on this page are taken from PubChem (US National Library of Medicine) and Wikidata. Grade-specific data — assay, moisture, particle size, packaging, shelf life — is issued per batch on the COA and is not published here.